O diretor da Unidade Clínica de Lípides do InCor doutor Raul Dias Santos colaborou na criação do mais recente consenso da Sociedade Internacional de Aterosclerose (IAS) e na Iniciativa de Redução de Risco Residual (R3i). Confira o abstract deste consenso abaixo, em inglês:
In the era of precision medicine, treatments that target specifc modifable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), ofer a key modifable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) ofers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the frst SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profle. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
O texto integral do consenso, em inglês, está em https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0864-7
 |
| Foto: Sergio Barbosa (SBDCD/InCor) |